## generation bio<sup>-</sup>

## Generation Bio to Present at Wedbush PacGrow Healthcare Conference 2021

August 3, 2021

CAMBRIDGE, Mass., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced today that Geoff McDonough, M.D., president and chief executive officer, will participate in a panel discussion at the Wedbush PacGrow Healthcare Conference 2021 on Tuesday, August 10 at 9:10 a.m. ET.

A live webcast of the panel will be available on the investor section of the company's website at <u>investors.generationbio.com</u>. A replay will be available there for 30 days following the event.

## **About Generation Bio**

Generation Bio is innovating genetic medicines to provide durable, redosable treatments for people living with rare and prevalent diseases. The company's non-viral platform incorporates a novel DNA construct called closed-ended DNA, or ceDNA; a unique cell-targeted lipid nanoparticle delivery system, or ctLNP; and a highly scalable capsid-free manufacturing process that uses its proprietary cell-free rapid enzymatic synthesis, or RES, to produce ceDNA. The platform is designed to enable multi-year durability from a single dose, to deliver large genetic payloads, including multiple genes, to specific tissues, and to allow titration and redosing to adjust or extend expression levels in each patient. RES has the potential to expand Generation Bio's manufacturing scale to hundreds of millions of doses to support its mission to extend the reach of genetic medicine to more people, living with more diseases, around the world.

For more information, please visit www.generationbio.com.

Contact:

Investors Maren Killackey Generation Bio mkillackey@generationbio.com 541-646-2420

## Media

Alicia Webb Generation Bio awebb@generationbio.com 847-254-4275

Stephanie Simon Ten Bridge Communications stephanie@tenbridgecommunications.com 617-581-9333